Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma

Open access
Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, McArthur, Grant A., Kudchakar, Ragini, Mahipal, Amit, Yamada, Yasuhide, Sullivan, Ryan, Arance, Ana, Kefford, Richard F., Carlino, Matteo S., Hidalgo, Manuel, Gomez-Roca, Carlos, Michel, Daniela, Seroutou, Abdelkader, Aslanis, Vassilios, Caponigro, Giordano, Stuart, Darrin D., Moutouh-de Parseval, Laure, Demuth, Tim, Dummer, Reinhard · 2017 · Clinical Cancer Research

Abstract

Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRAF-mutant melanoma. Experimental Design: The pharmacologic activity of encorafenib was first characterized preclinically. Encorafenib monotherapy was then tested across a range of once-daily (50–700 mg) or twice-daily (75–150 mg) regimens in a phase I, open-label, dose-escalation and -expansion study in adult patients with histologically confirmed advanced/metastatic BRAF-mutant melanoma. Study objectives were to determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), characterize the safety and tolerability and pharmacokinetic profile, and assess the preliminary antitumor activity of encorafenib. Results: Preclinical data demonstrated that encorafenib inhibited BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E–mutant melanoma models. In the dose-escalation phase, 54 patients (29 BRAFi-pretreated and 25 BRAFi-naïve) were enrolled. Seven patients in the dose-determining set experienced dose-limiting toxicities. Encorafenib at a dose of 300 mg once daily was declared the RP2D. In the expansion phase, the most common all-cause adverse events were nausea (66%), myalgia (63%), and palmar–plantar erythrodysesthesia (54%). In BRAFi-naïve patients, the overall response rate (ORR) and median progression-free survival (mPFS) were 60% and 12.4 months [95% confidence interval (CI), 7.4–not reached (NR)]. In BRAFi-pretreated patients, the ORR and mPFS were 22% and 1.9 months (95% CI, 0.9–3.7). Conclusions: Once-daily dosing of single-agent encorafenib had a distinct tolerability profile and showed varying antitumor activity across BRAFi-pretreated and BRAFi-naïve patients with advanced/metastatic melanoma. Clin Cancer Res; 23(18); 5339–48. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2923

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 198

Metadata

Authors
Delord, J.-P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R. F., Carlino, M. S., Hidalgo, M., Gomez-Roca, C., Michel, D., Seroutou, A., Aslanis, V., Caponigro, G., Stuart, D. D., Moutouh-de Parseval, L., Demuth, T., & Dummer, R.
Venue
Clinical Cancer Research
Published
2017-08-22
Volume
23
Issue
18
Pages
5339-5348
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2624834472
Cited by
198
References
5
FWCI
7.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2923
The paper
Delord, J.-P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R. F., Carlino, M. S., Hidalgo, M., Gomez-Roca, C., Michel, D., Seroutou, A., Aslanis, V., Caponigro, G., Stuart, D. D., Moutouh-de Parseval, L., . . . Dummer, R. (2017). Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2923

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.